Polycythemia Vera: Causes, Symptoms, Treatment, and When Phlebotomy Therapy is Indicated

Polycythemia vera is a bone marrow disease that causes abnormal overproduction of red blood cells. The increased cell volume thickens the blood and slows its flow, increasing the risk of thrombosis and vascular complications. The condition is chronic and requires regular hematological monitoring, as untreated it can progress to myelofibrosis or leukemia.

In this article, we will cover the causes, clinical manifestations, possible complications, and available therapeutic options, with a focus on the role of phlebotomy in controlling the disease’s progression.

What is Polycythemia Vera?

Photo source: Shutterstock.com

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm, defined by the clonal expansion of a hematopoietic stem cell, leading to excessive production of erythrocytes and, frequently, associated proliferation of granulocytes and platelets. Hematologic overproduction occurs independently of the physiological regulation of erythropoiesis, characterized by suppressed erythropoietin secretion and autonomous bone marrow proliferation.

The direct consequence of this hemoconcentration is increased plasma viscosity, which contributes to slowed blood flow, favoring the occurrence of arterial and venous thrombotic events, including myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism. In some cases, megakaryocytic hyperplasia and thrombocytosis can lead to paradoxical hemorrhagic complications, especially in the presence of platelet functional abnormalities.

From a molecular perspective, PV is closely associated with the JAK2 V617F mutation, detectable in over 95% of patients. This mutation generates constitutive activation of JAK2 tyrosine kinase, leading to aberrant signaling in the JAK-STAT pathway, involved in controlling hematopoietic cell proliferation and differentiation. The identification of this mutation has become a major diagnostic criterion, according to the WHO classification, and has driven the development of molecularly targeted therapies to modify disease progression.

The Disease – Prevalence and Natural History

Epidemiologically, the disease predominantly affects adults over 60 years of age, with an estimated prevalence of 1–3 cases per 100,000 population, and a slight male predominance. The natural history is often slow but requires careful hematological surveillance, as there is a risk of secondary transformation into post-polycythemic myelofibrosis or, more rarely, acute myeloid leukemia.

Therapeutic management aims to reduce red blood cell mass and prevent vascular complications. In low-risk forms, phlebotomy remains the method of choice for maintaining hematocrit below the thrombotic risk threshold. In high-risk cases (age >60 years, history of thrombosis), cytoreductive therapy is added, particularly with hydroxyurea or pegylated interferon. Low-dose antiplatelet therapy with aspirin is indicated prophylactically, in the absence of hemorrhagic contraindications.

In addition to conventional therapeutic measures, adjuvant interventions that may help reduce thrombotic risk by improving blood rheological properties are also being investigated. For instance, Omega-3 fatty acid supplementation has been associated in some studies with a reduction in systemic inflammation and platelet aggregation, but these interventions require further validation in controlled clinical settings.

[cta_produs style=”style_1″ product=”91518″ image=”https://aronia-charlottenburg.com/wp-content/uploads/2025/04/Ce-este-policitemia-vera_-Aronia-HERO-product.png”]

Causes and Risk Factors of Polycythemia Vera + What Role Does the JAK2 v617f (Janus Kinase 2) Mutation Play in the Proliferation Pathogenesis?

The etiology of polycythemia vera (PV) is not fully elucidated, but progress in understanding the underlying molecular mechanisms has highlighted fundamental genetic factors in disease development. The main pathogenic event identified is the JAK2 V617F point mutation, present in approximately 95% of PV patients. This mutation affects the JAK2 (Janus Kinase 2) gene, which codes for a tyrosine kinase involved in intracellular signal transmission within the JAK-STAT pathway, essential for regulating hematopoietic cell proliferation and differentiation.

Through constitutive activation of this signaling pathway, independent of physiological stimuli (such as erythropoietin), the JAK2 V617F mutation causes autonomous proliferation of hematopoietic stem cells, particularly on the erythroid lineage, but often also on the granulocytic and megakaryocytic lineages. This abnormal proliferation leads to the expansion of mutant cell clones, which gain a competitive advantage over normal hematopoietic cells.

However, the presence of the JAK2 mutation, while essential, is not the sole factor required for the development of the full polycythemia vera phenotype. It is considered that other additional mutations (e.g., in genes like TET2, ASXL1, DNMT3A, or less commonly, CALR) contribute to clonal progression, phenotypic heterogeneity, and the risk of progression to myelofibrosis or acute leukemia. Furthermore, interactions with epigenetic or environmental factors can significantly influence disease expression.

PV – Epidemiological Risk Factors

Epidemiologically, the risk of developing PV increases with age, with peak incidence reported around age 60, and males appear slightly more predisposed. Previous exposure to ionizing radiation or mutagenic substances has been mentioned as a possible predisposing factor, although data are not conclusive. In most cases, however, PV occurs sporadically, without a clear cause or evident risk factors in personal or family history.

Thus, the JAK2 V617F mutation is a central point in understanding PV pathogenesis, but the complete development of the disease involves a complex interplay between genetic factors and the individual biological context, accounting for phenotypic variability and differential patient response to treatment.

Symptoms of Polycythemia Vera

Photo source: Shutterstock.com

Polycythemia vera often progresses insidiously and may remain asymptomatic in its early stages. In many cases, the condition is diagnosed incidentally during routine hematological tests, which reveal abnormal increases in hemoglobin, hematocrit, and blood cell counts.

As the disease progresses, various clinical manifestations may appear, primarily caused by cellular overproduction and increased blood viscosity. Headache is one of the most common symptoms, often accompanied by dizziness, vertigo, visual disturbances (blurred vision, double vision), and tinnitus. In other words, all these signs reflect cerebral hypoperfusion secondary to slowed circulation.

Dyspnea on exertion and chronic fatigue are also frequently reported, associated with the reduced oxygen-carrying capacity of hyperviscous blood in efficiently oxygenating tissues.

PV – Suggestive Cutaneous Manifestations

Cutaneous manifestations can be suggestive clues for the disease. Facial erythema, plethora, and intense itching – especially that aggravated by contact with warm water (aquagenic pruritus) – are characteristic of PV. Erythromelalgia, characterized by pain, heat, and redness in the distal extremities, may also occur intermittently.

Splenomegaly is present in most patients, causing postprandial fullness, abdominal discomfort, or early satiety. In advanced forms, hepatomegaly may also occur.

The clinical picture may be complemented by symptoms such as night sweats, nosebleeds or gum bleeding, spontaneous bruising, burning sensation in the soles of the feet, and in some cases, thrombotic or ischemic episodes.

Without adequate treatment, the course of polycythemia vera can be marked by major vascular complications, but also by progression to post-polycythemic myelofibrosis or leukemic transformation, underscoring the importance of close monitoring and personalized therapy.

Diagnosis of Polycythemia Vera

The diagnosis of polycythemia vera involves a comprehensive evaluation, including laboratory tests, genetic investigations, and, in certain situations, bone marrow examination. The first step is usually a complete blood count, useful for identifying elevated levels of hemoglobin, hematocrit, and red blood cell count. In many cases, changes in white blood cell or platelet counts may also be observed.

To support clinical suspicion, testing for the JAK2 V617F mutation, present in most forms of polycythemia vera, is recommended. In situations where the mutation is absent, but the hematological profile suggests a possible myeloproliferative disorder, further testing for other relevant mutations, such as those located in exon 12 of the JAK2 gene, may be pursued.

Determining serum erythropoietin levels provides additional useful information for differentiating polycythemia vera from other forms of erythrocytosis. Low erythropoietin levels support a primary etiology, while elevated levels suggest a secondary cause.

Bone Marrow Biopsy – Myeloproliferative Confirmation

To confirm the myeloproliferative nature and exclude other hematological conditions, a bone marrow biopsy may be indicated. Microscopic evaluation typically reveals medullary hypercellularity with panmyelosis (erythroid, granulocytic, and megakaryocytic proliferation).

In cases with atypical presentations or in the presence of other clinical signs, the hematologist may recommend additional molecular testing, including analysis for CALR, MPL, or TET2 mutations, for a complete diagnostic differentiation.

Therapeutic Strategies in Polycythemia Vera + Treatment Approach for Polycythemia Vera Forms

Treatment for polycythemia vera aims to reduce thrombotic risk, control hematological and extramedullary symptoms, and maintain a stable quality of life. Effectively, the choice of therapy is based on individual risk assessment, considering factors such as patient age, history of thrombosis, and the presence of cardiovascular comorbidities.

Therapeutic phlebotomy is the primary intervention in low-risk forms, used for rapid reduction of hematocrit. The main objective is to maintain it below 45%, a value associated with a significant decrease in the incidence of thrombotic events. The frequency of procedures varies depending on red blood cell reaccumulation and individual tolerance.

Cytoreductive Therapy – Indications and Main Agents

In patients requiring repeated interventions or presenting increased thrombotic risk, initiation of cytoreductive therapy is indicated. Hydroxyurea is the first-line agent, with proven efficacy in controlling erythrocytosis, thrombocytosis, and leukocytosis. For young patients or in situations where molecular remission is sought, pegylated interferon alfa offers an important therapeutic alternative, with no known leukemogenic potential.

For refractory or intolerant forms to standard treatment, JAK inhibitors, such as ruxolitinib, offer clinical benefits by reducing spleen size, improving systemic symptoms, and enhancing overall well-being.

Low-dose antiplatelet therapy with aspirin is recommended for most patients, in the absence of contraindications, as a preventive measure against thrombosis. Aquagenic pruritus and other functional symptoms may require pharmacological adjuncts, such as antihistamines or serotonin reuptake inhibitors. In severe cases, phototherapy or complementary systemic treatments may be employed.

Phlebotomy as the Primary Treatment for Polycythemia Vera

As mentioned in previous sections, therapeutic phlebotomy is the first-line intervention in the management of polycythemia vera, with the primary goal of rapidly reducing hematocrit and preventing thrombotic complications associated with blood hyperviscosity. This procedure is particularly recommended for patients with low thrombotic risk, in whom immediate initiation of cytoreductive therapy is not necessary.

From a pathophysiological standpoint, controlled extraction of a blood volume leads to a decrease in red blood cell mass and, consequently, a reduction in plasma viscosity. As a result, microcirculation flow is improved, tissue oxygenation becomes more efficient, and symptoms caused by hypervolemia, such as headache, dizziness, visual disturbances, or itching, are reduced.

The therapeutic protocol involves drawing approximately 450–500 ml of blood per session, initially every two to three weeks, until a target hematocrit value below 45% is achieved. Maintaining this threshold is crucial, as clinical studies have demonstrated a significant reduction in the risk of thrombotic events at this level.

Phlebotomy – Advantages and Tolerability

In addition to therapeutic efficacy, phlebotomy has the advantage of lacking cytotoxic effects, thus avoiding complications associated with drug therapy, such as myelosuppression or the risk of leukemic transformation. Therefore, the method is well-tolerated and remains a cornerstone option in forms with a favorable risk profile.

However, the frequent use of phlebotomy also has limitations. The procedure does not influence platelet or white blood cell counts, parameters often elevated in polycythemia vera. Furthermore, repeated red blood cell removal can deplete iron stores, potentially leading to functional iron deficiency syndrome, manifesting as fatigue, cognitive disturbances, and reduced exercise capacity.

Consequently, regular monitoring of iron status is necessary, as well as adjustment of phlebotomy frequency based on the evolution of biological parameters and clinical tolerance. In cases of intolerance or inefficiency, cytoreductive therapy may be used, particularly in patients with increased thrombotic risk or those requiring frequent interventions.

What to Eat with Polycythemia Vera?: Recommended Diet and Lifestyle

Photo source: Shutterstock.com

Diet is an important adjuvant factor in controlling the progression of polycythemia vera. Lifestyle behaviors are also important adjuvant factors in controlling the progression of polycythemia vera. These supplement pharmacologic treatment. These supplement regular clinical monitoring. Adopting a balanced nutritional regimen contributes to reducing cardiovascular risk. It contributes to maintaining adequate hematological homeostasis.

First and foremost, maintaining a normal body weight is recommended. The aim is to reduce systemic pressure on the circulatory system. This aspect is particularly important in the context of the blood hyperviscosity characteristic of polycythemia vera. Adequate hydration plays an essential role in maintaining functional blood viscosity. A daily intake of at least 2 liters of fluids is recommended. Fluids should preferably be in the form of still water. Fluids should preferably be in the form of sugar-free infusions.

Diet – Antioxidants and Nutrients

The daily food structure should include natural sources of antioxidants. Examples of natural antioxidant sources include fresh vegetables. Examples of natural antioxidant sources include fresh fruits. Especially those that are richly pigmented. These can help combat oxidative stress. They can contribute to combating systemic inflammation. Incorporating omega-3 polyunsaturated fatty acids is important. These are found in ocean fish (salmon). These are found in ocean fish (sardines). These are found in ocean fish (mackerel). They support lipid balance. They may have a beneficial effect on platelet reactivity. Protein sources must be carefully selected. Emphasis should be placed on lean proteins from white meat. Emphasis should be placed on lean proteins from fish. Emphasis should be placed on lean proteins from legumes. The goal is to maintain muscle mass. The goal is to support metabolic function.

It is advisable to avoid high consumption of saturated fats. It is advisable to avoid high consumption of ultra-processed foods. It is advisable to avoid high consumption of products with high sugar content. It is advisable to avoid high consumption of products with high salt content. Red meat can stimulate uric acid production. Organ meats can stimulate uric acid production. Purine-rich foods can stimulate uric acid production. These should be consumed in moderation. Moderate consumption is particularly important in the presence of hyperuricemia.

Moderate physical activity, performed regularly, benefits peripheral circulation. It reduces systemic inflammation. It supports psychological balance. Low-impact forms of exercise are recommended for the joints. Examples include brisk walking. Other examples include swimming. Another example is therapeutic gymnastics. Physical exertion should be accompanied by adequate hydration. It should be adapted to individual tolerance. The aim is to avoid the onset of hypoperfusion symptoms. Examples of symptoms include dizziness. Another example is pronounced fatigue.

Prognostic and Evolutionary Complications in Polycythemia Vera

As a chronic hematological disease with slow progression, its complications arise from the uncontrolled proliferation of hematopoietic cells and the changes induced by blood hyperviscosity and medullary hypercellularity.

Therefore, thrombotic complications are the most common, representing the primary cause of morbidity and mortality associated with the disease. They can occur at both arterial (stroke, myocardial infarction, peripheral ischemia) and venous (deep vein thrombosis, pulmonary embolism) levels. Factors influencing thrombotic risk include advanced age, history of thrombosis, persistent leukocytosis, and suboptimal hematocrit control.

Another possible evolution is transformation into secondary myelofibrosis, a process involving progressive development of medullary fibrosis, onset of anemia, reduced exercise tolerance, and progressive spleen enlargement. Fibrotic transformation affects approximately 10–20% of patients within the first 10 years of the disease, requiring treatment adjustments and re-evaluation of therapeutic goals.

In rarer cases, the disease can progress to acute myeloid leukemia. The transformation rate is between 5–10% at 15–20 years after diagnosis. Factors associated with this risk include disease duration, prolonged administration of cytotoxic agents, and the patient’s biological age. Post-PV leukemia is typically aggressive and associated with a poor prognosis.

Prognostic assessment in polycythemia vera is based on several factors: age at diagnosis, cardiovascular status, therapeutic response, and adherence to monitoring. The introduction of modern therapies, such as JAK inhibitors or pegylated interferon, has improved patients’ long-term outlook, offering increased chances of reducing evolutionary risks and stabilizing the clinical picture.

Adapting Daily Life to Polycythemia Vera Symptoms

Living with polycythemia vera involves careful adaptation to the challenges posed by a chronic condition, but with proper management and adequate medical support, patients can maintain a good functional level and a satisfactory quality of life.

First and foremost, managing symptoms, especially chronic fatigue, is an important objective in daily monitoring. In this regard, establishing balanced routines, alternating periods of activity with rest, and optimizing sleep can reduce the impact of exhaustion.

Necessary adaptations in the professional environment may include requesting flexible hours or ergonomic adjustments, depending on individual needs. Open communication with employers and the medical team allows for efficient integration of therapeutic requirements into active life.

Aquagenic Pruritus – Control and Care Measures

To control cutaneous manifestations, such as aquagenic pruritus, the use of hypoallergenic hygiene products, avoidance of high temperatures during showers, and application of emollients after bathing are recommended. These measures can reduce skin irritation and discomfort.

Maintaining consistent physical activity, adapted to physical capacity, has positive effects on circulation, psychological balance, and overall well-being. Low-impact activities, such as walking, swimming, or stretching exercises, can be gradually incorporated into the daily routine.

Lastly, to support emotional balance, psychological counseling sessions or participation in support groups can be beneficial. Furthermore, constant symptom monitoring and close collaboration with the medical team allow for early treatment adjustments and prevention of complications. Integrating these measures into the daily routine significantly contributes to maintaining an active and autonomous life, despite the diagnosis of polycythemia vera.

In conclusion, polycythemia vera remains a serious hematological disease, but one that can be effectively controlled when recognized early and treated appropriately. With well-chosen therapeutic interventions and constant medical supervision, risks can be significantly reduced, and the disease’s progression can be managed. Although a cure does not exist, maintaining hematological parameters within safe limits and adapting lifestyle allow for a stable clinical course and a good long-term quality of life.

References:

1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. DOI: 10.1002/ajh.26008;

2. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2018;132(18):1931-1940. DOI: 10.1182/blood-2018-06-834796;

3. Vannucchi AM, Guglielmelli P. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematology Am Soc Hematol Educ Program. 2017;2017(1):480-488. DOI: 10.1182/asheducation-2017.1.480;

4. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057-1069. DOI: 10.1038/s41375-018-0077-1;

5. Mesa R, Jamieson C, Bhatia R, et al. Myeloproliferative Neoplasms, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(10):1158-1195. DOI: 10.6004/jnccn.2019.0058.

Photo source: Shutterstock.com